Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.1K
Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.6K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Tonic Signaling Code Predicts CAR-T Cell Efficacy in Diffuse Midline Glioma.

bioRxiv : the preprint server for biology·2025
Same author

Living on the edge: Uncommitted OPC-like cells drive glioblastoma invasiveness.

Developmental cell·2025
Same author

The Eyes Absent family members EYA4 and EYA1 promote PLK1 activation and successful mitosis through tyrosine dephosphorylation.

Nature communications·2024
Same author

Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition.

Clinical cancer research : an official journal of the American Association for Cancer Research·2022
Same author

The Eyes Absent proteins in development and in developmental disorders.

Biochemical Society transactions·2021
Same author

The multi-functional eyes absent proteins.

Critical reviews in biochemistry and molecular biology·2020

Related Experiment Video

Updated: Jul 12, 2025

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

913

IGF-1R targeting in cancer - does sub-cellular localization matter?

Upendra K Soni1, Liam Jenny1, Rashmi S Hegde2

  • 1Division of Developmental Biology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

Journal of Experimental & Clinical Cancer Research : CR
|October 20, 2023
PubMed
Summary
This summary is machine-generated.

Insulin-like growth factor receptor (IGF-1R) targeted cancer therapies failed due to resistance and toxicity. Sub-cellular localization of IGF-1R may be a predictive biomarker for future treatment strategies.

Keywords:
BiomarkersCombination therapyIGF-1RNuclear IGF-1RReplication stressSarcomaTherapeuticscancer

More Related Videos

Subcellular Fractionation for ERK Activation Upon Mitochondrial-derived Peptide Treatment
07:55

Subcellular Fractionation for ERK Activation Upon Mitochondrial-derived Peptide Treatment

Published on: September 25, 2017

7.9K
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.0K

Related Experiment Videos

Last Updated: Jul 12, 2025

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

913
Subcellular Fractionation for ERK Activation Upon Mitochondrial-derived Peptide Treatment
07:55

Subcellular Fractionation for ERK Activation Upon Mitochondrial-derived Peptide Treatment

Published on: September 25, 2017

7.9K
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.0K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Insulin-like growth factor receptor (IGF-1R) is a key target in cancer therapy.
  • Previous IGF-1R-targeted drugs faced challenges with resistance, toxicity, and lack of patient stratification.
  • Despite clinical trial failures, there's renewed interest in IGF-1R therapeutics.

Purpose of the Study:

  • To review the history of IGF-1R targeted drug development.
  • To explore the potential of IGF-1R sub-cellular localization as a predictive biomarker.
  • To investigate the correlation between IGF-1R localization and treatment susceptibility.

Main Methods:

  • Review of clinical trial data and scientific literature.
  • Analysis of resistance and toxicity mechanisms.
  • Exploration of biomarker-driven patient stratification.

Main Results:

  • Early clinical trials highlighted resistance and toxicity issues with IGF-1R inhibitors.
  • Sub-cellular localization of IGF-1R emerged as a potential predictive biomarker.
  • Lack of patient stratification limited the success of prior therapeutic strategies.

Conclusions:

  • Next-generation IGF-1R therapies require predictive biomarkers for patient selection.
  • Sub-cellular localization of IGF-1R shows promise for guiding treatment decisions.
  • Combination therapies incorporating IGF-1R inhibitors may benefit from this biomarker approach.